Lupus and Sex Drive: What 13 Studies of 1,511 Women Found

Lupus and sex drive are connected in the pooled research, and the honest version is wider and shakier than the confident answers online. Across 13 studies covering 1,511 women with systemic lupus erythematosus and 2,246 healthy controls, 58.8% scored in the range questionnaires call sexual dysfunction, and the odds against healthy women came out at 2.64. Both figures carry wide confidence intervals, and the earlier reviews disagree with each other. In 2017 a pooling of two studies found no difference on desire at all. What changed since then is the number of studies. So lupus is a context for what happened to your desire. It is a long way from a verdict on it.

Figures from Dai et al. 2026 (PMID 42158876) and Jin et al. 2021 (PMID 33210559). Both pool observational studies, so every figure here is an association.

Is it the lupus, or is it me?

Type the question into a search bar and the answer comes back fast and sure of itself: lupus wrecks your libido, here is the protocol that fixes it. The pooled research is slower and far less tidy. Something is measurable at the group level, its size swings by review, and one of the six reviews here found nothing at all on desire.

This page goes one disease deep. The wider picture, pooling lupus with rheumatoid arthritis, Sjogren's syndrome and the rest, lives in our guide to autoimmune disease and sex drive. Here we stay with the lupus-only reviews, including the lupus-only reviews that hub does not cite.

This is the seventh diagnosis we have walked into with the same question, after the thyroid and low libido connection, PCOS, endometriosis, diabetes, and multiple sclerosis. The pattern repeats. A diagnosis arrives, it explains a real part of what you feel, and then it gets stretched to cover the whole. Once it owns the whole experience, the parts that respond to attention stop getting any. Our wider guide on why your libido is so low walks through those parts.

What 13 studies of 1,511 women found

Dai and colleagues searched four databases from inception to July 1, 2025 for everything published on sexual function in women with systemic lupus erythematosus. Thirteen studies met the criteria, covering 1,511 women with lupus and 2,246 healthy controls. Under a random-effects model, 58.8% scored in the dysfunction range, on a 95% confidence interval running from 46.1% to 71.6%.

Read that interval before the headline. It spans twenty-five percentage points. Somewhere between roughly half and seven in ten women with lupus score below the questionnaire's threshold, and the studies underneath disagree enough that the authors chased the heterogeneity with subgroup analysis and meta-regression.

Against the healthy controls, the same review put the odds at 2.64 (95% CI 1.27 to 5.47). That sits clear of 1.0, so the association holds. It is also more than four times as far from 1.0 at the top as at the bottom, which is what a pooled estimate looks like when thirteen small studies are asked to agree.

Every study in that pool is observational. Nobody was randomised to lupus, so none of these figures says which way the arrow runs, or how much of the gap belongs to the disease against everything travelling with it.

The number that crosses the line

The most useful paper here is older and smaller, and it puts the disagreement in the open. Jin and colleagues pooled eight studies covering 758 people with lupus and 1,724 controls, and reported a relative risk of 1.80 (95% CI 1.12 to 2.87).

Split by sex, the picture changes shape. Men came out at a relative risk of 2.98 (95% CI 2.41 to 3.68), a tight interval well clear of 1.0. Women came out at 1.56 (95% CI 0.99 to 2.48). That lower bound sits on the line, so in that review the women's estimate never clearly separated from the controls.

The same paper does report women scoring lower on the questionnaire total, at a weighted mean difference of -0.224 (95% CI -0.441 to -0.078). The authors add that participant age and study quality might influence the results.

The men's row is the strongest signal in this literature, worth knowing given how much lupus writing is addressed to women only. Any page calling the women's evidence settled has skipped a review.

Six reviews, one direction, sharper each time

This question has been asked six times in nine years, and the answers move as studies pile up.

Yin and colleagues went first, in 2017, and found almost nothing: two studies, 236 patients. On desire there was no significant difference against healthy controls (P = .24; MD -0.44, 95% CI -1.17 to 0.29), and the same held for every other individual section, pain included (P = .17; MD -0.50, 95% CI -1.22 to 0.22). Only the questionnaire total reached significance, at MD -1.24 (95% CI -1.97 to -0.50). Their conclusion asked for larger populations.

That null is the honest starting point. Two studies in 2017, thirteen in 2026, and the picture firmed up as the evidence arrived. Nothing about the disease changed in between.

Liu and colleagues sat in the middle, in 2022. From 367 records searched to November 9, 2021 they kept five studies, covering 710 women with lupus and 2,059 healthy women, and found a significant decrease in the total scores of the Female Sexual Function Index. Their conclusion names desire and pain among the areas affected. That paper carries a published correction, issued eleven days later, and we could not read what it changed: the publisher's page sits behind a browser challenge and the PubMed notice has no abstract.

Review by review: what each pooled, what it reported, and its main caveat.

Review	Studies	People	Headline figure	Caveat
Yin 2017, women	2	236 patients	No significant difference on desire (P = .24; MD -0.44, -1.17 to 0.29)	Two studies is barely a meta-analysis
Jin 2021, both sexes	8	758 with lupus, 1,724 controls	RR 1.80 (1.12 to 2.87); men 2.98 (2.41 to 3.68); women 1.56 (0.99 to 2.48)	The women's interval crosses 1.0; age and study quality might influence it
Liu 2022, women	5	710 with lupus, 2,059 healthy	Significant decrease in total questionnaire scores; desire and pain named	Cross-sectional only, and a published correction we could not read
Minopoulou 2023, any rheumatic disorder	68	5,457 women, mean age 43.7	63% (56% to 69%); pooled questionnaire total 19.7 (18.4 to 21)	Heterogeneity 94% and 97%. No separate lupus figure in the abstract
Zhu 2025, men	9	5,002 articles screened	Erection problems OR 7.44 (5.00 to 11.06); higher FSH and LH; lower sperm count	The largest effect here on the smallest base
Dai 2026, women	13	1,511 with lupus, 2,246 healthy	58.8% (46.1% to 71.6%); odds 2.64 (1.27 to 5.47)	The largest lupus-only pool, on very wide intervals. No predictors reported

Where lupus sits in the wider rheumatic picture

Zoom out and the numbers get bigger and vaguer. Minopoulou and colleagues pooled 68 studies covering 5,457 women with systemic autoimmune rheumatic disorders, mean age 43.7 years (SD 12.9), and reported an overall prevalence of 63% (95% CI 56% to 69%), with heterogeneity of 94%. The pooled questionnaire total was 19.7 points (95% CI 18.4 to 21), heterogeneity 97%.

Counting only sexually active women, prevalence fell to 60% (95% CI 53% to 67%) and the total rose to 22 points (95% CI 20.8 to 23.1). Sjogren's syndrome (74%, 95% CI 58% to 87%) and systemic sclerosis (69%, 95% CI 54% to 83%) reported the highest levels. Lupus has no separate number in that abstract, and the review concludes that sexual function looked impaired whichever disorder the women had.

What none of these reviews measured

Here is the part most articles skip. None of the lupus reviews here pools fatigue, depression, disease activity, steroid dose, kidney involvement or pain as predictors of desire. The abstracts report prevalence, risk and questionnaire scores, and stop short of what carried them.

So when you read that lupus flares kill your sex drive, or that the exhaustion is the mechanism, or that a drug is the culprit, that is somebody's inference. It might well be right. It is absent from this evidence, and no pooled review has measured the lupus medications against desire either.

What women with lupus describe in their own words is a stack: tired all the time in a way sleep does not touch, joints that hurt, a body that changed with treatment, and a low hum of waiting for the next flare. That is lived context and we are flagging it as such, because none of it was measured above. Where those threads have been pooled on their own terms, we have written them up: chronic pain and low sex drive, depression and low libido, and brain fog and sex drive. If your bloodwork came back unremarkable and you were sent home with nothing to work on, normal labs, low libido is the guide.

Lupus and sex drive in men

Men are a small share of lupus patients and a smaller share of the writing about it, and the one review that looked found the largest effect here. Zhu and colleagues screened 5,002 articles published between January 2000 and December 2024 and kept nine studies.

Erection problems came out at an odds ratio of 7.44 (95% CI 5.00 to 11.06). Men with lupus also showed higher follicle-stimulating hormone (mean difference 4.02, 95% CI 1.47 to 6.57) and higher luteinising hormone (mean difference 2.21, 95% CI 1.10 to 3.32), and lower sperm count (mean difference -0.54, 95% CI -0.86 to -0.22).

Nine observational studies is a thin base for an odds ratio that large, and an interval from 5.00 to 11.06 says the estimate is imprecise. What it supports is a referral. Hormones are a blood test and a doctor's conversation, and our general guide is low libido in men.

What helped, in the one review that looked

One systematic review has gone looking for what works. Baniotopoulos and colleagues searched to April 2022 and found seven studies covering 426 women with lupus, rheumatoid arthritis and systemic sclerosis, across five treatment classes: androgen therapy, PDE-5 inhibitors, exercise, education and local creams.

Two things worked. Standardized patient education improved scores, and so did an eight-week aerobic walking programme. Local creams improved pain during sex in women with systemic sclerosis. Two things did not. Testosterone did not significantly improve scores in women with lupus, and tadalafil did not in women with systemic sclerosis. The testosterone result is the one to carry, because hormones are the internet's standard answer to low desire and this is the only review that has tested them here.

Hold all four results loosely. The review's own words are that the majority of the studies were of low methodological quality and that no definite conclusions can be drawn. Seven small studies across three diseases is where research begins. The walking result has the least to lose by trying, and our page on exercise and libido covers that evidence in people without a rheumatic diagnosis.

What to bring to your rheumatology appointment

Appointments are short and this is the item most likely to get dropped. Say it out loud in the first two minutes, because no clinician will raise it for you.

1. The timeline. When did it change, and what else changed in the same months: a flare, a new prescription, a dose change, a hospital stay. No pooled review measured any of that, so your timeline is better evidence than the literature.
2. The kidney and blood-pressure questions. Both are common in lupus and both decide what is safe for you to take.
3. Fatigue and mood, on their own terms. Neither was pooled as a predictor here, both are treatable in their own right, and both deserve their own conversation.
4. The walking evidence. An eight-week aerobic walking programme has the most support in the one treatment review, thin as that review admits it is.
5. Testosterone, before anyone sells it to you. In that same review it did not significantly improve scores in women with lupus.
6. The supplement question, asked with the bottle in your hand. Let the person who knows your kidneys and your medication list read the label.

The everyday levers, and where a botanical fits

Start with who this section is not for. Kidney involvement, cardiovascular risk and blood-pressure medication are all common in lupus, and they are what NUUD's own label warns about: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For many readers of this article, that sentence is the answer. Talk to your doctor first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since lupus fatigue and broken sleep feed each other. Sleep, libido and testosterone covers that.
• Movement you can sustain. The one treatment review's best result was a walking programme, and exercise and libido covers the wider picture.
• Care for your mood and your pain, both named out loud and taken as seriously as your labs.
• Time and safety, with a partner or on your own, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for lupus, for inflammation, for fatigue, or for any medication you take, and it has no role in managing an autoimmune disease or any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If you have kidney involvement, a heart condition or take blood-pressure medication, the label says no, and your rheumatologist decides the rest. If your doctor has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

You have probably been handed two unhelpful answers already: a shrug at the end of an appointment that ran out of time around your bloodwork, and a confident voice online telling you lupus killed your sex drive and here is the protocol that brings it back.

The research supports neither. Around six in ten women with lupus score in the dysfunction range, on an interval running from half of them to seven in ten. The odds against healthy women are real at 2.64 and imprecise from 1.27 to 5.47. One review found the women's risk touching the line of no difference, and the first review on this question found no difference on desire at all.

So your drive being nowhere to be found has a context, and that context is looser and more workable than anyone selling you a protocol wants to admit. You have an autoimmune disease that has been asking a great deal of your body for years, a medication list, a fatigue load, and a life that keeps going anyway. Any one of those flattens wanting. If you have been quietly wondering whether you are broken: no. Nothing is wrong with you. Low libido in women walks through the rest.

Keep reading

• Autoimmune disease and sex drive
• Chronic pain and low sex drive
• Depression and low libido
• Multiple sclerosis and sex drive
• Why is my libido so low?

Frequently asked questions

Does lupus affect sex drive?
Yes, and the pooled numbers are large, though the intervals around them are wide. Across 13 studies covering 1,511 women with systemic lupus erythematosus and 2,246 healthy controls, 58.8% scored in the range questionnaires call sexual dysfunction (95% CI 46.1% to 71.6%), and the odds against healthy women came out at 2.64 (95% CI 1.27 to 5.47). Every study pooled there is observational, so that is an association and no direction of cause can be read off it. An earlier review of eight studies put the women's relative risk at 1.56 (95% CI 0.99 to 2.48), crossing the line of no difference, so the reviews do not fully agree.

Is it the lupus or is it me?
It is most likely the lupus together with everything that travels alongside it, and no pooled review has separated those. The reviews on this page report prevalence, risk and questionnaire scores. None pools fatigue, depression, disease activity, steroid dose, kidney involvement or pain as predictors of desire, so anyone telling you which one is doing the work is guessing. Around six in ten women with lupus land in the same range you did, on a wide interval. Nothing is wrong with you, and the timeline of your own flares and medication changes is better evidence than this literature is.

Does lupus lower sex drive in men too?
The men's numbers are the largest on this page and rest on the least data. One review screened 5,002 articles and kept nine studies, reporting erection problems at an odds ratio of 7.44 (95% CI 5.00 to 11.06), higher follicle-stimulating hormone and luteinising hormone, and lower sperm count. A separate review that split its pooled risk by sex put men at a relative risk of 2.98 (95% CI 2.41 to 3.68) against 1.56 for women. Nine observational studies is a thin base for an odds ratio that large, and a reason to raise it with a rheumatologist.

What helps with low sex drive when you have lupus?
One systematic review has tested treatments in this population, and it is a thin one. Across seven studies covering 426 women with lupus, rheumatoid arthritis or systemic sclerosis, standardized patient education and an eight-week aerobic walking programme improved scores. Testosterone did not significantly improve scores in women with lupus, and tadalafil did not in systemic sclerosis. The review's own words are that the majority of the studies were of low methodological quality and that no definite conclusions can be drawn, so take those results to your rheumatologist and do not stop or change your medication without your doctor.

Can I take a botanical supplement if I have lupus?
Ask your rheumatologist first, and for many readers the answer will be no. NUUD's own label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients, and kidney involvement, cardiovascular risk and blood-pressure medication are all common in lupus. NUUD is a botanical supplement built around desire in general, and it has no role in lupus, in any other autoimmune disease, or in anything your medication is doing. Bring the label to the person who knows your chart.

References

1. Dai X, Ding H, Mao D, Huang J. Prevalence of female sexual dysfunction among women with systemic lupus erythematosus: a systematic review and meta-analysis. Frontiers in Immunology. 2026;17:1673871. https://pubmed.ncbi.nlm.nih.gov/42158876/
2. Jin Z, Yang C, Xiao C, Wang Z, Zhang S, Ren J. Systemic lupus erythematosus and risk of sexual dysfunction: A systematic review and Meta-Analysis. Lupus. 2021;30(2):238-247. https://pubmed.ncbi.nlm.nih.gov/33210559/
3. Liu M, Dou J, Wang Q. The effect of systemic lupus erythematosus on sexual function in women: an updated meta-analysis based on cross-sectional studies. Advances in Rheumatology. 2022;62(1):24. https://pubmed.ncbi.nlm.nih.gov/35787296/
4. Liu M, Dou J, Wang Q. Correction: The effect of systemic lupus erythematosus on sexual function in women: an updated meta-analysis based on cross-sectional studies. Advances in Rheumatology. 2022;62(1):26. https://pubmed.ncbi.nlm.nih.gov/35841080/
5. Yin R, Xu B, Li L, et al. The impact of systemic lupus erythematosus on women's sexual functioning: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(27):e7162. https://pubmed.ncbi.nlm.nih.gov/28682869/
6. Minopoulou I, Pyrgidis N, Tishukov M, et al. Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis. Rheumatology (Oxford). 2023;62(3):1021-1030. https://pubmed.ncbi.nlm.nih.gov/35951753/
7. Baniotopoulos P, Pyrgidis N, Minopoulou I, et al. Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review. Sexual Medicine Reviews. 2022;10(4):520-528. https://pubmed.ncbi.nlm.nih.gov/36210093/
8. Zhu J, Zhu Q, Li X, Shen T, Shi X, Zhao T. Systemic lupus erythematosus and male reproductive health: A systematic review and meta-analysis. Autoimmunity Reviews. 2025;24(4):103742. https://pubmed.ncbi.nlm.nih.gov/39788440/

This article is for general education and is not medical advice. Systemic lupus erythematosus is a medical condition that only a licensed clinician can diagnose and manage. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing lupus, any autoimmune disease, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.